12:00 AM
 | 
Jan 26, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lucentis ranibizumab regulatory update

Novartis received Japanese approval of Lucentis ranibizumab to treat subfoveal wet age-related macular degeneration (AMD)....

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >